HealthLumen Blog
NEWS: England faces £1.2 billion in healthcare costs if Covid-19 lockdown alcohol consumption trends persist to 2035
When the Covid-19 pandemic hit in early 2020, drinking habits shifted significantly for many. But what happens when those pandemic-era drinking habits stick around? Recent research from HealthLumen explores the long-term consequences of changes in alcohol consumption during the pandemic, and the findings are stark: if those patterns continue until the end of 2035, England could face nearly 10,000 additional premature deaths, over 147,000 excess cases of disease, and £1.2 billion extra in healthcare costs.
Read
Demonstrating the value of cascade screening using microsimulation modelling: A pathway to faster diagnosis and improved patient outcomes for genetic diseases
Earlier diagnosis can make all the difference for individuals with genetic diseases. Delayed diagnosis hinders timely disease management and treatment access, meaning that progression to late-stage disease can occur more rapidly, likely leading to a significant increase in the health and economic burden of these conditions for patients, their families, and healthcare systems. Screening programs aim to identify individuals with genetic conditions earlier, with cascade screening in particular providing one way to help transform outcomes for patients.
Read
The Inside CKD online hub: Turning research into policy action
As part of AstraZeneca’s Accelerate Change Together (ACT) on CKD programme to drive chronic kidney disease (CKD) change across the healthcare ecosystem, the Inside CKD project stream projected the clinical and economic burden of CKD from 2022 to 2027 across 31 countries and regions. The results have recently been compiled into a comprehensive portal on the Inside CKD website.
Read
NEWS: HealthLumen launches AlleleAtlas, a tool for estimating the prevalence of rare genetic diseases
HealthLumen has today announced the launch of AlleleAtlas, the genetic variant prevalence projection tool. The tool has been developed to bring a valuable resource to the rare disease community, including those engaged in rare disease research and therapeutics in the pharmaceutical, biotech and research spaces, and for patient advocacy organisations aiming to raise awareness.
Read